TRANSBIL

Title: A trial looking at the Mcm5 protein test for diagnosing cancer of the bile duct, gallbladder or pancreas (TRANSBIL)

Full title: TRANSBIL (Biliary MCM5 Study)- Diagnosis of pancreatobiliary malignancy by detection of minichromosome maintenance proteins in cytological specimens

Why is this trial being carried out?

Cancer of the bile duct, gall bladder or pancreas is usually diagnosed with blood tests, scans and a biopsy, but diagnosis is not always straightforward.

The new Mcm5 test (so called because it looks for the Mcm5 protein) might be better at diagnosing these cancers, although doctors do not yet know how good it will be.

This trial is to make sure that the Mcm5 test is accurate and reliable. If so, it can be more widely used to diagnose cancer in future. Patients taking part will have the Mcm5 test as well as the usual tests, not instead of them.

Who is the trial suitable for?

This trial is suitable for patients who have cancer of the bile duct, gall bladder or pancreas or who are having tests for these cancers. It is also suitable for patients who have a benign (non-cancerous) condition of the bile duct, gall bladder or pancreas. Your doctor(s) will explain any other requirements to join the trial.

Trial centre

London

Recruitment start date: March 2009

Recruitment end date: February 2014    

For more information

CancerHelp UK